Instructions for use of Sotoracib (AMG510)

1. Introduction to drugs

Sotoracib (AMG510) is an innovative drug targeting the KRAS G12C mutation, providing a new treatment option for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced multiple treatments.

2. Applicable groups and diseases

This drug is designed for adult patients with locally advanced or metastatic non-small cell lung cancer who carry the KRAS G12C mutation. Patients must be confirmed by a U.S. Food and Drug Administration (FDA)-approved test before starting this drug and must have undergone at least one systemic treatment.

3. Possible adverse reactions

Patients may experience a range of adverse reactions when using sotoraxib. Common ones include diarrhea, musculoskeletal pain, nausea, fatigue, and toxic reactions resulting from abnormal liver function. More serious side effects may include pneumonia and severe diarrhea. In addition, laboratory testing may show abnormalities such as lymphopenia, decreased hemoglobin, and elevated liver enzymes.

4. Medication guidance

It is recommended that patients take 960 mg of sotoraxib orally once daily Make sure to take the medicine at the same time every day, whether before or after meals, to maintain stable blood concentration. Tablets should be swallowed whole and should not be chewed, crushed or divided. For patients with difficulty swallowing, the tablets can be dispersed in 120 mL of non-carbonated room temperature water (be careful not to use other liquids), stir and drink immediately, and rinse the container with additional water to ensure complete intake of the drug.

5. Storage method

Please store Sotoraxibu in a dry, dark place, the recommended temperature is 20°C to 25°C, short-term storage is allowed in the range of 15°C to 30°C. Keep medicine out of the reach of children.

6. Mechanism of action

Sotorasiib precisely inhibitsKRAS G12C mutation, locking the protein in an inactive state, thereby blocking the growth and spread signals of cancer cells. This mechanism of action is highly selective and is only effective against tumor cells carrying the KRAS G12C mutation, promoting the apoptosis of these cells while minimizing the impact on normal cells.

7. Overtreatment

Specific data regarding overdose with sotoraxib are insufficient. However, based on observations from clinical trials, overdose may lead to exacerbation of adverse effects such as diarrhea, nausea, vomiting, fatigue, and elevated liver enzymes. If overdose is suspected, contact a medical professional or go to a hospital immediately.

8. Use restrictions

Sotoraxib is not recommended for use by women who are breastfeeding because the drug may be passed to the infant through breast milk, causing serious adverse reactions. If female patients are breastfeeding or planning to breastfeed, please choose other appropriate treatment options under the guidance of a doctor. At the same time, it should also be banned for patients who are allergic to this drug.